Navigation Links
VitaPath Genetics Raises $6M in Series A Round
Date:9/10/2009

FOSTER CITY, Calif., Sept. 10 /PRNewswire/ -- VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious but preventable diseases. The company's initial focus is a validated genetic test for Spina Bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician. The financing proceeds will be used to complete the validation of the company's first assay and prepare for commercial launch.

"VitaPath Genetics addresses a significant and underserved area of medicine - understanding and treating preventable diseases. Whereas most medicine is delivered after the fact, VitaPath provides actionable diagnostics to identify and prevent those most at risk from developing a disease or condition," Goldberg explained. "Diagnostics such as those developed by the VitaPath team will play a key role in achieving the nation's goal of preventing disease, improving patient care and reducing healthcare costs."

VitaPath Genetics CEO Bruce Cohen added, "We are delighted to have MDV and X/Seed support the development of a whole new generation of actionable genetic assays that are based on solid science. Our unique approach to discovery and validation, originally developed in the laboratory of Jasper Rine at UC/Berkeley, will make it possible to identify and safely remediate mutations that would otherwise impair health."

About VitaPath Genetics

VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious, but preventable, disease. The company's initial focus is a validated genetic test for Spina Bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician.

For more information visit: www.vpgenetics.com.

About MDV-Mohr Davidow Ventures

MDV has been a leading Silicon Valley venture capital firm for more than 25 years. The firm funds and mentors entrepreneurs, scientists and young companies involved in redefining business, technology and medicine. MDV invests around three major themes: Personalizing Medicine; Powering the Planet; and Driving the Digital World. The firm partners with entrepreneurs seeking to transform healthcare through the use of more meaningful and personalized information. Category-leading life science companies funded by MDV include: Adamas; Artemis Health; CardioDx; Corventis; Crescendo Bioscience; iRhythm; Navigenics; Pacific Bioscience; ParAllele (AFFX); RainDance Technologies; Tethys Bioscience; and Ventus Medical. MDV has $2 billion dollars under management. For more information visit: http://www.mdv.com.

About X/Seed Capital

X/Seed Capital is an independent, seed-focused, venture fund providing de-novo start-up capital for entrepreneurs pursuing breakthrough innovation. X/Seed was founded in 2006 and is based in California's Silicon Valley. For more information visit: http://www.xseedcap.com.


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The American Society of Human Genetics Hosts 59th Annual Meeting
2. Viral Genetics Completes Second Major Debt Conversion
3. The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States
4. Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
5. March of Dimes Celebrates 50th Anniversary of Genetics Short Course
6. Teen Behaviors Stem From Genetics, Environment
7. Interleukin Genetics Announces Strategic Divestment of Alan James Group
8. BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations
9. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
10. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
11. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/23/2017)... 2017  Leaf Healthcare, recognized for developing one ... pressure ulcer prevention, will unveil its comprehensive mobility ... Care Nurses, National Teaching Institute and Critical Care ... Leaf Patient Monitoring System is the first mobility ... The system seamlessly tracks patient movement throughout the ...
Breaking Medicine Technology: